Skip to main content

Table 4 Multivariate analysis

From: Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study

Factors

Overall survival

Progression-free survival

 

p - value

Odds ratio

95 % confidence interval

p- value

Odds ratio

95 % confidence interval

Comparison 1

RT field

0.31

  

0.15

  

 ENI

 

1.21

0.84–1.73

 

1.32

0.90–1.93

 IFRT

 

1

  

1

 

M-stage

<0.0001

  

0.0001

  

 M0

 

0.47

0.33–0.67

 

0.47

0.32–0.69

 M1

 

1

  

1

 

Comparison 2

RT field

0.036

  

0.024

  

 ENI

 

1.48

1.03–2.13

 

1.55

1.06–2.26

 IFRT

 

1

  

1

 

Age (y.o.)

0.092

  

0.49

  

 −70

 

0.74

0.52–1.05

 

1.15

0.77–1.72

 71-

 

1

  

1

 

Comparison 3

RT field

0.011

  

0.0009

  

 ENI

 

1.60

1.11–2.29

 

1.90

1.30–2.79

 IFRT

 

1

  

1

 

T-stage

<0.0001

  

<0.0001

  

 T1

<0.0001

0.22

0.13–0.39

<0.0001

0.11

0.053–0.23

 T2

0.0008

0.38

0.21–0.67

0.0010

0.36

0.19–0.66

 T3

0.0021

0.53

0.36–0.80

0.013

0.59

0.39–0.89

 T4

 

1

  

1

 

Comparison 4

RT field

0.017

  

0.0073

  

 ENI

 

1.75

1.10–2.76

 

1.91

1.19–3.07

 IFRT

 

1

  

1

 

N-stage

<0.0001

  

<0.0001

  

 N0

<0.0001

0.21

0.10–0.43

<0.0001

0.15

0.070–0.33

 N1

0.0090

0.38

0.19–0.79

 

0.44

0.21–0.91

 N2

0.13

0.54

0.24–1.21

 

0.55

0.24–1.24

 N3

 

1

  

1

 

Comparison 5

RT field

0.082

  

0.040

  

 ENI

 

1.38

0.96–1.97

 

1.48

1.02–2.16

 IFRT

 

1

  

1

 

Location

0.53

  

0.14

  

 Cervix

0.44

0.66

0.23–1.90

0.14

0.34

0.081–1.44

 Upper thorax

0.15

0.69

0.43–1.14

0.097

0.66

0.41–1.08

 Middle thorax

0.33

0.79

0.49–1.27

0.038

0.59

0.37–0.97

 Lower thorax

 

1

  

1

 

Comparison 6

0.26

  

0.065

  

RT field

 

1.24

0.85–1.82

 

1.45

0.98–2.16

 ENI

 

1

  

1

 

 IFRT

      

CTx cycle

0.002

  

0.083

  

 1

0.0012

2.29

1.39–3.78

0.50

1.20

0.70–2.04

 2

0.30

1.27

0.81–1.98

0.27

0.78

0.50–1.22

 3

0.48

0.78

0.39–1.55

0.042

0.45

0.21–0.97

 4

 

1

  

1

 

Comparison 7

RT field

0.099

  

0.017

  

 ENI

 

1.35

0.94–1.93

 

1.58

1.09–2.30

 IFRT

 

1

  

1

 

Stage

<0.0001

  

<0.0001

  

 I

<0.0001

0.30

0.17–0.53

<0.0001

0.12

0.051–0.28

 II

0.0009

0.43

0.26–0.71

0.015

0.53

0.32–0.88

 III

0.12

0.73

0.49–1.09

0.53

0.88

0.58–1.33

 IV

 

1

  

1

 

Comparison 8

RT field

0.16

  

0.10

  

 ENI

 

1.30

0.90–1.88

 

1.38

0.94–2.03

 IFRT

 

1

  

1

 

Age (y.o.)

0.028

1.02

1.003–1.045

 

1.002

0.98–1.02

M-stage

<0.0001

     

 M0

 

0.42

0.29–0.60

 

0.47

0.31–0.70

 M1

 

1

  

1

 

Comparison 9

RT field

0.34

  

0.054

  

 ENI

 

1.21

0.82–1.77

 

1.48

0.99–2.20

 IFRT

 

1

  

1

 

Stage

<0.0001

  

<0.0001

  

 I

<0.0001

0.22

0.12–0.42

<0.0001

0.094

0.033–0.27

 II

0.0018

0.42

0.24–0.72

0.048

0.58

0.34–0.99

 III

0.14

0.74

0.49–1.11

0.75

0.93

0.60–1.44

 IV

 

1

  

1

 

CTx cycle

0.0006

  

0.066

  

 1

0.0002

2.62

1.58–4.35

0.12

1.52

0.89–2.59

 2

0.13

1.42

0.90–2.24

0.95

0.98

0.62–1.55

 3

0.62

0.84

0.42–1.67

0.078

0.50

0.24–1.08

 4

 

1

  

1

 
  1. RT Radiation therapy, CTx Chemotherapy, ENI Elective node irradiation, IFRT Involved-field radiation therapy
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us